Esophageal Neoplasm Clinical Trial
— FAISA-CORPPSOfficial title:
FEASIBILITY STUDY on the Use of a DIGITAL PLATFORM for Physical and Psychosocial RECONDITION After Major Neoplastic Surgery
The incidence of cancer in France has increased by +135% to reach nearly 400,000 new cases in 2018. The ten-year cancer control strategy 2021-2030 and the health innovation plan have defined strategic axes. Almost all of these axes are addressed in our project. Firstly, the main objective of our study is to improve the quality of life of patients. Secondly, pharyngolaryngeal and oesophageal cancers are among the cancers with a poor prognosis in adults. Thirdly, the project provides access to personalised supportive care for all patients at all times. Finally, the secondary objectives of this study are the prevention of post-operative complications (infectious, thrombo-embolic, pain...).
Status | Not yet recruiting |
Enrollment | 30 |
Est. completion date | September 2023 |
Est. primary completion date | September 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Hospitalized for initial surgical management of esophageal or laryngeal cancer - Admitted to a conventional ward after partial oesophagectomy or total laryngectomy in a neoplastic setting - Patient giving consent to participate in the study - Affiliated to the compulsory health insurance scheme, regardless of the scheme Exclusion Criteria: - Patient who did not follow the previously described course of care prior to admission to the ward - Esophagectomy with total circular pharyngo-laryngectomy - Total esogastrectomy - Illiterate, visually impaired patient - Minor, or adult under guardianship or curatorship, under judicial protection, person deprived of liberty |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Lille | ENGIE, Fondation Boulanger, Santelys Association |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Acceptability rate | Realization of the ratio between the number of inclusion proposals and the number of accepted inclusions. | At 1 year | |
Secondary | Adherence to exercise intervention program: Number of login | Discharge from hospital if it occurs before 30 days or at Day 30 | ||
Secondary | Adherence to exercise intervention program: Number of exercises completed | Discharge from hospital if it occurs before 30 days or at Day 30 | ||
Secondary | Adherence to exercise intervention program: type of exercises completed | Discharge from hospital if it occurs before 30 days or at Day 30 | ||
Secondary | Adherence to exercise intervention program: retention rate | Discharge from hospital if it occurs before 30 days or at Day 30 | ||
Secondary | Satisfaction by the System Usability Scale | Discharge from hospital if it occurs before 30 days or at Day 30 | ||
Secondary | Classification de Clavien-Dindo | Evaluation of the incidence of postoperative complications based on the Clavien-Dindo classification grade II | At day 30 | |
Secondary | Visual Analogue Scale | Measure the pain in the scale from 0 to 10 | Before and after each activity | |
Secondary | Instant Well-Being Evaluation (IWBE) | It consists of a graduated scale: the patient must position a cursor, the position on the left corresponding to "I feel very well" and the position on the right to "I do not feel well". The patient is guided by a pictogram (happy, neutral or sad face) | Baseline, Discharge from hospital if it occurs before 30 days and at Day 30 | |
Secondary | Warwick-Edinburgh Mental Wellbeing Scales | The well-being and theu quality of life will be assessed using the Warwick-Edinburgh Mental Wellbeing Scales Each item is scored on a range from 1 to 5. The total score will be between 14 and 70, with lower scores indicating poor wellbeing, and higher scores indicating greater wellbeing. Very low wellbeing is defined as a score of = 45. A substantial decrease in wellbeing is a decrease by 5 or more points. | Baseline, Discharge from hospital if it occurs before 30 days and at Day 30 | |
Secondary | EuroQuol 5 Dimensions (EQ-5D-5L) | The quality of life will be assessed using the EuroQuol 5 Dimensions The EQ-5D-5L questionnaire will be used to estimate the impact on subjects' health-related quality of life and provides a description of subjects' problems by dimensions (descriptive system), a score for overall self-rated health (visual analogue scale [VAS]) as well as an index score (EQ-5D-5L index). EQ-5D index score range: 0 to 1 and EQ-5D-VAS: range 0 to 100. A higher score indicates better self reported health status. | Baseline, Discharge from hospital if it occurs before 30 days and at Day 30 | |
Secondary | European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaires (EORTC-QLQ-C30) | The quality of life will be assessed using the EORTC-QLQ-C30 The Quality of life questionnaire (QLQ-C30) contains 29 items dealing with fatigue, pain, nausea and vomiting, general condition and social, emotional and cognitive functions. It is currently used in many clinical trials in oncology | Baseline, Discharge from hospital if it occurs before 30 days and at Day 30 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05176002 -
Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.
|
Phase 1/Phase 2 | |
Terminated |
NCT02601079 -
Endodrill vs. Conventional Biopsy. Diagnostics and Genetic Analysis
|
N/A | |
Active, not recruiting |
NCT01745107 -
Efficacy of Intensity Modulated Radiation Therapy After Surgery in Early Stage of Esophageal Carcinoma;
|
Phase 3 | |
Active, not recruiting |
NCT02969473 -
Definitive Concurrent Chemoradiotherapy With Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin in Patients With Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
Recruiting |
NCT04481100 -
CCRT With Itraconazole in Locally Advanced Squamous Esophageal Cancer
|
Phase 2 | |
Terminated |
NCT03108885 -
Measuring Cell Free DNA During the Course of Treatment for Esophageal Cancer as a Marker of Response and Recurrence
|
||
Recruiting |
NCT00288119 -
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
|
||
Terminated |
NCT01870791 -
Study of Additive Omega-3 Fish Oil to Palliative Chemotherapy to Treat Oesophagogastric Cancer
|
Phase 2 | |
Active, not recruiting |
NCT00431756 -
Novel Biomarkers in the Neoplastic Progression of Barrett's Esophagus
|
||
Not yet recruiting |
NCT05736705 -
Monopolar and Bipolar in Esophageal ESD
|
N/A | |
Completed |
NCT02395705 -
Neoadjuvant Chemotherapy Versus Surgery Alone for Esophageal Squamous Cell Carcinoma
|
Phase 3 | |
Completed |
NCT02033213 -
Volume Restriction in Esophageal Carcinoma Surgery: Randomized Clinical Trial
|
N/A | |
Terminated |
NCT00653107 -
Palliation Dysphagia Cancer Oesophagus Stent+Brachytherapy Versus Brachytherapy Only
|
Phase 3 | |
Completed |
NCT01927016 -
Outcomes After Esophageal Cancer Surgery
|
N/A | |
Completed |
NCT02558504 -
Radiofrequency in the Treatment of Barrett's Oesophagus
|
Phase 4 | |
Active, not recruiting |
NCT02636088 -
Definitive Chemoradiotherapy and Cetuximab in the Treatment of Locally Advanced Esophageal Cancer
|
Phase 2 | |
Terminated |
NCT00423150 -
Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED)
|
Phase 2 | |
Completed |
NCT00318903 -
Irinotecan and Taxotere With Radiotherapy as Preoperative Treatment in Resectable Esophageal Cancer
|
Phase 2 | |
Recruiting |
NCT02583087 -
ESD for the Treatment of Early Barrett's Neoplasia
|
N/A | |
Active, not recruiting |
NCT04489368 -
Response Prediction to Neoadjuvant Chemoradiation in Esophageal Cancer Using Artificial Intelligence & Machine Learning
|